SCHEMBL6449424

SCHEMBL6449424

CCOc1ccc(C=C2SC(=S)NC2=O)cc1-c1cc2c(cc1C)C(C)(C)CC=C2C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.57
PDE3A Q14432 5/20 0.57
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
DYRK1A Q13627 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
PIM1 P11309 1/20 0.52
PIM3 Q86V86 1/20 0.52
DYRK2 Q92630 1/20 0.52
PIM2 Q9P1W9 1/20 0.52
MGAM O43451 1/20 0.49
GAA P10253 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
POLB P06746 2/20 0.46
HTT P42858 1/20 0.46
IGF1R P08069 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449423 1.00 PDE4B (0.57) PDE4BPDE3AMEN1KMT2ADYRK1A
SCHEMBL6449507 0.92 IGF1R (0.54) PDE4BPDE3APIM1PIM3PIM2
SCHEMBL6449502 0.92 IGF1R (0.54) PDE4BPDE3APIM1PIM3PIM2
SCHEMBL6451521 0.87 PDE4B (0.42) PDE4BPDE3AMEN1KMT2ADYRK1A
SCHEMBL6451524 0.87 PDE4B (0.42) PDE4BPDE3AMEN1KMT2ADYRK1A
SCHEMBL6450655 0.86 MYC (0.44) PDE4BPDE3AMEN1KMT2ADYRK1A
SCHEMBL6450651 0.86 MYC (0.44) PDE4BPDE3AMEN1KMT2ADYRK1A
SCHEMBL6450607 0.82 RXRA (0.48) PDE4BPIM1PIM3PIM2IGF1R
SCHEMBL6450610 0.82 RXRA (0.48) PDE4BPIM1PIM3PIM2IGF1R
SCHEMBL6450617 0.80 RXRA (0.62) PDE4BPIM1PIM3PIM2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases INCYTE CORPORATION 2005-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases HSD17B10, IDH2, INSR PDE4B 4301/4885PDE3A 4462/4885MEN1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.